Treatment of Severe Nasal Congestion in Elderly Patients with Viral Upper Respiratory Infection
For an elderly patient with extreme head congestion from a viral upper respiratory infection, prescribe intranasal corticosteroids (mometasone furoate 200 mcg or fluticasone propionate 2 sprays per nostril once daily) as first-line therapy, with optional addition of nasal saline irrigation for immediate symptomatic relief. 1
Why Intranasal Corticosteroids Are First-Line
Intranasal corticosteroids are the most effective monotherapy for nasal congestion, controlling all four major nasal symptoms with onset of action within 12 hours and superior sustained efficacy compared to all other medication classes. 1
In post-viral acute rhinosinusitis (which presents as severe congestion), mometasone furoate 200 mcg twice daily produced significant symptom improvements versus both placebo and amoxicillin, with similar adverse event rates. 2
These agents are particularly appropriate for elderly patients because they avoid the cardiovascular and central nervous system risks associated with oral and topical decongestants, which are especially hazardous in this population. 1
Proper Administration Technique
Instruct the patient to direct the spray laterally away from the nasal septum to prevent epistaxis, local irritation, and the rare risk of septal perforation. 1
If severe obstruction limits initial steroid delivery, consider a brief (≤3 days maximum) course of topical oxymetazoline applied first, followed 5 minutes later by the intranasal corticosteroid—but only if the patient has no significant cardiovascular disease. 1
Adjunctive Symptomatic Relief
Add nasal saline irrigation as it provides symptomatic relief with minimal risk of adverse effects and is particularly useful in viral upper respiratory infections. 2, 1
Recommend acetaminophen or ibuprofen for pain relief and fever if present. 2
What NOT to Do in Elderly Patients
Avoid first-generation oral antihistamines entirely as they produce marked sedation and anticholinergic effects that are especially hazardous in the elderly. 1
Do not prescribe oral decongestants (pseudoephedrine) as first-line therapy in elderly patients due to heightened cardiovascular and CNS side-effect risk, including small increases in systolic blood pressure and heart rate. 1
Strictly limit topical decongestants (oxymetazoline) to 3 days maximum if used at all, as rhinitis medicamentosa can develop as early as day 3-4 of continuous use. 1
Do not prescribe antibiotics for viral upper respiratory infections, as they provide no benefit and cause adverse effects including rash, gastrointestinal upset, and antibiotic resistance. 2
Expected Timeline and Follow-Up
Most patients with viral upper respiratory infections feel better within 7 days, and by 15 days about 90% are cured or improved. 2
Advise the patient to follow up if symptoms worsen or exceed 2 weeks, as this may indicate progression to bacterial rhinosinusitis requiring different management. 2
Continue intranasal corticosteroids for 2-4 weeks for optimal benefit, as symptom reduction becomes more pronounced after 15 days of use. 2, 1
Common Pitfall to Avoid
The most critical error is prescribing topical decongestants beyond 3 days or as monotherapy, which creates dependency and worsens congestion long-term through rhinitis medicamentosa. 1 In elderly patients with cardiovascular comorbidities, using oral sympathomimetic decongestants without considering cardiac risk is equally problematic. 1